Supratherapeutic Tacrolimus Concentrations With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients Requiring Hospitalization: A Case Series Using Rifampin for Reversal
- PMID: 35854994
- PMCID: PMC9277654
- DOI: 10.1093/ofid/ofac238
Supratherapeutic Tacrolimus Concentrations With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients Requiring Hospitalization: A Case Series Using Rifampin for Reversal
Abstract
Nirmatrelvir/ritonavir was recently granted emergency use authorization for mild to moderate coronavirus disease 2019. Drug-drug interactions between ritonavir and tacrolimus are underappreciated by nontransplant providers. We describe 2 solid organ transplant recipients prescribed nirmatrelvir/ritonavir for outpatient use who developed tacrolimus toxicity requiring hospitalization and were managed with rifampin for toxicity reversal.
Keywords: COVID-19; drug interactions; nirmatrelvir/ritonavir; tacrolimus.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Figures
Similar articles
-
Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion.Am J Health Syst Pharm. 2024 Jun 24;81(13):e345-e352. doi: 10.1093/ajhp/zxae032. Am J Health Syst Pharm. 2024. PMID: 38347740
-
Nirmatrelvir/ritonavir Use With Tacrolimus in Lung Transplant Recipients: A Single-center Case Series.Transplantation. 2023 May 1;107(5):1200-1205. doi: 10.1097/TP.0000000000004394. Epub 2022 Oct 28. Transplantation. 2023. PMID: 36525555 Free PMC article.
-
Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.BMC Nephrol. 2023 Apr 15;24(1):99. doi: 10.1186/s12882-023-03154-w. BMC Nephrol. 2023. PMID: 37061677 Free PMC article.
-
Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies.Front Immunol. 2023 Apr 4;14:1150341. doi: 10.3389/fimmu.2023.1150341. eCollection 2023. Front Immunol. 2023. PMID: 37081880 Free PMC article. Review.
-
"Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".Transpl Infect Dis. 2023 Apr;25(2):e14037. doi: 10.1111/tid.14037. Epub 2023 Feb 27. Transpl Infect Dis. 2023. PMID: 36847419 Free PMC article. Review.
Cited by
-
Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug-drug interactions.J Int Med Res. 2024 May;52(5):3000605241247705. doi: 10.1177/03000605241247705. J Int Med Res. 2024. PMID: 38698526 Free PMC article.
-
Ritonavir: 25 Years' Experience of Concomitant Medication Management. A Narrative Review.Infect Dis Ther. 2024 May;13(5):1005-1017. doi: 10.1007/s40121-024-00959-6. Epub 2024 Apr 12. Infect Dis Ther. 2024. PMID: 38609668 Free PMC article. Review.
-
Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.Transpl Int. 2024 Mar 26;37:12360. doi: 10.3389/ti.2024.12360. eCollection 2024. Transpl Int. 2024. PMID: 38596505 Free PMC article.
-
Case report: Supratherapeutic tacrolimus concentrations with nirmatrelvir/ritonavir in a lung transplant patient: a case report using Rifampin for reversal.Front Pharmacol. 2023 Nov 10;14:1285078. doi: 10.3389/fphar.2023.1285078. eCollection 2023. Front Pharmacol. 2023. PMID: 38026995 Free PMC article.
-
Gestion de l'interaction entre le tacrolimus et le nirmatrelvir/ritonavir dans le traitement de la COVID-19 en transplantation d'organe solide.Can J Hosp Pharm. 2023 Jul 5;76(3):254-256. doi: 10.4212/cjhp.3352. eCollection 2023 Summer. Can J Hosp Pharm. 2023. PMID: 37409140 Free PMC article. No abstract available.
References
-
- Centers for Disease Control and Prevention . COVID data tracker. 2022. https://covid.cdc.gov/covid-data-tracker/#trends_totalcases. Accessed 25 February 2022.
-
- Pfizer, Inc . Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid. New York: Pfizer, Inc; 2021.
-
- van Maarseveen EM, Rogers CC, Trofe-Clark J, van Zuilen AD, Mudrikova T. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review. AIDS Patient Care STDS 2012; 26:568–81. - PubMed
-
- Katzenmaier S, Markert C, Riedel K-D, Burhenne J, Haefeli WE, Mikus G. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther 2011; 90:666–73. - PubMed